Impact of pharmacy services on cystic fibrosis medication adherence
ConclusionThe study demonstrated that pharmacy services improved adherence to dornase alfa. (Source: Pediatric Pulmonology)
Source: Pediatric Pulmonology - June 13, 2017 Category: Respiratory Medicine Authors: Jeffery T. Zobell, Elizabeth Schwab, Dave S. Collingridge, Cody Ball, Robert Nohavec, Fadi Asfour Tags: ORIGINAL ARTICLE: CYSTIC FIBROSIS Source Type: research
The in vitro mucolytic effect of xylitol and dornase alfa on chronic rhinosinusitis mucus
ConclusionXylitol and dornase alfa may be efficacious mucolytics, encouraging the breakdown of postoperative mucus crusts and the reduction of viscoelasticity and viscosity of wet mucus. In vivo study is required to evaluate the potential of these agents in treating recalcitrant CRS. (Source: International Forum of Allergy and Rhinology)
Source: International Forum of Allergy and Rhinology - June 1, 2017 Category: Allergy & Immunology Authors: Tim Hardcastle, Ravi Jain, Fiona Radcliff, Sharon Waldvogel ‐Thurlow, Melissa Zoing, Kristi Biswas, Richard Douglas Tags: ORIGINAL ARTICLE Source Type: research
EPS5.1 Harnessing the UK registry data: how does long-term dornase alfa (DNase) use affect lung function?
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - June 1, 2017 Category: Respiratory Medicine Authors: S.J. Newsome, R. Keogh, R.M. Daniel, CF EpiNet Tags: E-Poster Sessions Source Type: research
Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
CONCLUSION: Together, our study showed that these methods could suitably characterize antibiotic and mucolytic-containing dry powder inhalers.
PMID: 28420285 [PubMed - as supplied by publisher] (Source: Drug Development and Industrial Pharmacy)
Source: Drug Development and Industrial Pharmacy - April 21, 2017 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Mucoactive agents for chronic, non ‐cystic fibrosis lung disease: A systematic review and meta‐analysis
ABSTRACT
Inhaled mucoactive agents are used in respiratory disease to improve mucus properties and enhance secretion clearance. The effect of mannitol, recombinant human deoxyribonuclease/dornase alfa (rhDNase) and hypertonic saline (HS) or normal saline (NS) are not well described in chronic lung conditions other than cystic fibrosis (CF). The aim of this review was to determine the benefit and safety of inhaled mucoactive agents outside of CF. We searched Medline, Embase, CINAHL and CENTRAL for randomized controlled trials investigating the effects of mucoactive agents on lung function, adverse events (AEs), health‐re...
Source: Respirology - April 11, 2017 Category: Respiratory Medicine Authors: Benjamin J. Tarrant, Caitlin Le Maitre, Lorena Romero, Ranjana Steward, Brenda M. Button, Bruce R. Thompson, Anne E. Holland Tags: Systematic Review Source Type: research
Adherence to therapies in cystic fibrosis: a targeted literature review.
Authors: Narayanan S, Mainz JG, Gala S, Tabori H, Grossoehme D
Abstract
INTRODUCTION: Cystic fibrosis (CF) is a life-shortening condition with no cure. Available therapies relieving the symptoms of CF are complex and time-consuming. A comprehensive review assessing adherence to different CF therapies, association of adherence with outcomes, and factors influencing adherence could inform optimal patient management strategies. Areas covered: A targeted literature review of studies published from 2010-2016 assessed adherence to CF therapies. Nineteen studies qualified for inclusion. Adherence to CF therapies ...
Source: Expert Review of Respiratory Medicine - January 22, 2017 Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
Pilot study of dornase alfa (Pulmozyme) therapy for acquired ventilator ‐associated infection in preterm infants
ConclusionTreatment with dornase alfa is safe and treated infants had some improvement in FiO2 requirement but no improvement in MAP. A larger randomized trial is needed to evaluate the efficacy of this therapy. Pediatr Pulmonol. 2016; 9999:XX–XX. © 2016 Wiley Periodicals, Inc. (Source: Pediatric Pulmonology)
Source: Pediatric Pulmonology - January 2, 2017 Category: Respiratory Medicine Authors: Melissa Scala, Deborah Hoy, Maria Bautista, Judith Jones Palafoutas, Kabir Abubakar Tags: Original Article: Neonatal Lung Disease Source Type: research
Evaluation of Inhaled Dornase Alfa Administration in Non-Cystic Fibrosis Patients at a Tertiary Academic Medical Center
Conclusions:
Inhaled dornase alfa is commonly prescribed to improve atelectasis and secretions in a non-cystic fibrosis patient population at a tertiary academic medical center. (Source: Journal of Pharmacy Practice)
Source: Journal of Pharmacy Practice - September 18, 2016 Category: Drugs & Pharmacology Authors: Torbic, H., Hacobian, G. Tags: Research Articles Source Type: research
Dornase alfa for cystic fibrosis
(Source: Paediatric Respiratory Reviews)
Source: Paediatric Respiratory Reviews - September 14, 2016 Category: Respiratory Medicine Authors: CL Yang, M Chilvers, M Montgomery, SJ Nolan Source Type: research
Setting up of a homecare system for high cost nebulisers in a paediatric cystic fibrosis centre
Conclusion
A planned method and agreed standard operation procedure was key to effectively capture and repatriate all patients while at the same time keeping the increase on workload for the pharmacy team to a minimum. The fact of having a strong pharmacy presence as part of the multidisciplinary team attending CF clinics and ward rounds was vital in making this work. (Source: Archives of Disease in Childhood)
Source: Archives of Disease in Childhood - August 16, 2016 Category: Pediatrics Authors: Chorro-Mari, V., Christiansen, N. Tags: Poster presentations Source Type: research
Timing of dornase alfa inhalation for cystic fibrosis.
CONCLUSIONS: The current evidence derived from a small number of participants does not indicate that inhalation of dornase alfa after airway clearance techniques is more or less effective than the traditional recommendation to inhale nebulised dornase alfa 30 minutes prior to airway clearance techniques, for most outcomes. For children with well-preserved lung function, inhalation before airway clearance may be more beneficial for small airway function than inhalation after. However, this result relied on a measure with high variability and studies with variable follow up. In the absence of strong evidence to indicate that...
Source: Cochrane Database of Systematic Reviews - July 25, 2016 Category: Journals (General) Authors: Dentice R, Elkins M Tags: Cochrane Database Syst Rev Source Type: research
Chronic Rhinosinusitis in Patients with Cystic Fibrosis
Publication date: July–August 2016 Source:The Journal of Allergy and Clinical Immunology: In Practice, Volume 4, Issue 4 Author(s): Daniel L. Hamilos Chronic rhinosinusitis (CRS) is highly prevalent in patients with cystic fibrosis (CF) and accounts for significant morbidity and contribution to CF lung disease. Mutations of the cystic fibrosis transmembrane regulator gene occur with increased prevalence in patients with CRS without CF, suggesting some contribution to CRS pathophysiology. Nasal polyps (NPs) occur with increased prevalence in patients with CF of all ages and have a more neutrophilic appearance with f...
Source: The Journal of Allergy and Clinical Immunology: In Practice - July 6, 2016 Category: Allergy & Immunology Source Type: research
Efficacy measures for clinical trials: A review series
The last two decades have witnessed considerable expansion in cystic fibrosis (CF) treatment options and associated improvements in patient outcomes. Whereas in the early 1990s limited therapeutic options included systemic antibiotics, inhaled bronchodilators, and pancreatic enzymes, the commercial development of inhaled dornase alfa began a parade of randomized controlled trials of medications to mitigate the respiratory complications of cystic fibrosis that continues to this day. Today, many more treatment options targeting the sequelae of CF lung disease are available, including multiple aerosolized antibiotics, hyperto...
Source: Journal of Cystic Fibrosis - June 13, 2016 Category: Respiratory Medicine Authors: Patrick A. Flume, Donald R. VanDevanter Tags: Editorial Source Type: research
Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis — Results of a multicenter, prospective, randomized, double-blind, controlled trial
Chronic rhinosinusitis is a hallmark of Cystic fibrosis (CF) impairing the patients' quality of life and overall health. However, therapeutic options have not been sufficiently evaluated. Bronchial inhalation of mucolytic substances is a gold standard in CF therapy. Previously, we found that sinonasal inhalation of dornase alfa as vibrating aerosol reduces symptoms of chronic rhinosinusitis more effectively than NaCl 0.9% (net treatment benefit: −5.87±2.3 points, p=0.017; SNOT-20 total score). This multicenter study compares the effect of NaCl 6.0% vs. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - June 4, 2016 Category: Respiratory Medicine Authors: Jochen G. Mainz, Ulrike Schumacher, Katja Sch ädlich, Julia Hentschel, Christiane Koitschev, Assen Koitschev, Joachim Riethmüller, Freerk Prenzel, Olaf Sommerburg, Bärbel Wiedemann, Doris Staab, Wolfgang Gleiber, Rainald Fischer, James F. Beck, Christi Tags: Original Article Source Type: research
